Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Latest news on fluoroquinolones].

E Bergogne-Bérézin1

  • 1Laboratoire de microbiologie, CHU Bichat-Claude Bernard, 46, rue Henri Huchard, 75877 Paris.

Presse Medicale (Paris, France : 1983)
|December 25, 2002
PubMed
Summary

New fluoroquinolones aim to broaden antimicrobial spectrum and improve activity against resistant bacteria. Early tests show superior efficacy compared to existing treatments, though clinical relevance needs further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefuroxime: pharmacokinetic study in bronchial secretions.

Proceedings of the Royal Society of Medicine·2010
Same author

[After the "era of antibiotics", the "era of resistance"].

Presse medicale (Paris, France : 1983)·2004
Same author

[Pharmacologic innovations, the fluoroquinolone model].

Presse medicale (Paris, France : 1983)·2003
Same author

[Anti-infective agents and bacterial resistance, monitor, eradicate or avoid resistance?].

Presse medicale (Paris, France : 1983)·2002
Same author

[Drawbacks and problems of infectiology today].

Presse medicale (Paris, France : 1983)·2002
Same author

Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit.

Journal of chemotherapy (Florence, Italy)·2002

Area of Science:

  • Microbiology
  • Pharmacology

Context:

  • Emerging bacterial resistance necessitates novel antimicrobial agents.
  • Fluoroquinolones represent a critical class of antibiotics with evolving applications.

Purpose:

  • To develop new fluoroquinolones with an expanded antimicrobial spectrum, including activity against anaerobic bacteria.
  • To enhance efficacy against Gram-positive bacteria resistant to current therapies.
  • To improve the binding affinity of fluoroquinolone molecules to bacterial target enzymes.

Summary:

  • New fluoroquinolone development focuses on widening antimicrobial spectrum and enhancing activity against resistant Gram-positive bacteria.
  • Preclinical data indicate significantly superior antimicrobial activity for new fluoroquinolones compared to existing agents.
  • Concerns exist regarding the clinical correlation of in vitro data for older fluoroquinolones, particularly concerning therapeutic failures in patients with high minimum inhibitory concentrations (MICs).

Impact:

  • Potential for improved treatment outcomes in challenging bacterial infections.
  • Addresses the growing threat of antimicrobial resistance.
  • Informs future drug development and clinical trial design for fluoroquinolones.

Related Experiment Videos